Cerebral perfusion in untreated, controlled, and uncontrolled hypertension

Isabel N Christie1, Rowan Windsor1, Henk JMM Mutsaerts2, Therese Tillin3, Carole H Sudre3, Alun D Hughes4, Xavier Golay5, Alexander V Gourine1 and Patrick S Hosford1

Abstract
This study evaluated the association between systemic arterial blood pressure and cerebral perfusion in 740 participants of the UK’s largest tri-ethnic study with measurements of cerebral blood flow (CBF) performed using arterial spin labelling MRI. A significant negative correlation between blood pressure, age and CBF was observed across the patient cohort. The lowest CBF values were recorded in the group of patients with hypertension that were prescribed with anti-hypertensive drugs, but uncontrolled on medication. These findings confirm that hypertension is associated with reduced cerebral perfusion and highlight the importance of blood pressure control for the benefit of maintaining brain blood flow.

Keywords
Cerebral blood flow, brain, hypertension, MRI, perfusion

Received 16 March 2022; Revised 9 June 2022; Accepted 8 July 2022

Hypertension affects 1.5 billion people worldwide and its prevalence increases as the global population ages. Hypertension is now considered one of the leading causes of age-related cognitive impairment and is strongly associated with reduced cerebral blood flow (CBF). There is significant evidence that reduced brain perfusion, sustained over many years, leads to progressive cognitive decline, development of dementia and neurodegenerative disease, such as Alzheimer’s disease. The effect of anti-hypertensive drugs on CBF in hypertensive patients remains unclear. Different studies reported decreases, increases or no changes in CBF in response to anti-hypertensive medication. Two recent systematic reviews highlighted that many of these studies were small, underpowered, and showed evidence of a significant (moderate-to-high) risk of bias.

Here we evaluated the association between systemic arterial blood pressure and cerebral perfusion in a cohort of patients recruited in the Southall and Brent Revisited (SABRE) study, the UK’s largest tri-ethnic longitudinal study involving 740 participants with measurements of cerebral perfusion performed using arterial spin labelling MRI and quantified using a

1Centre for Cardiovascular and Metabolic Neuroscience, Neuroscience, Physiology and Pharmacology, University College London, London, UK
2Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands
3MRC Unit for Lifelong Health & Ageing, Population Science & Experimental Medicine, Faculty of Population Health Sciences, University College London, London, UK
4Institute of Cardiovascular Science, Population Science & Experimental Medicine, Faculty of Population Health Sciences, University College London, London, UK
5Queen Square Institute of Neurology, University College London, London, UK

Corresponding authors:
Alexander V Gourine, University College London, Gower Street, London, WC1E 6BT, UK.
Email: a.gourine@ucl.ac.uk
Patrick S Hosford, University College London, Gower Street, London, WC1E 6BT, UK.
Current address: RIKEN Center for Brain Science, Wako, Saitama, Japan.
Email: patrick.hosford@riken.jp
single compartment model without partial volume correction. The study cohort included white European (41.7%), first South Asian (33.7%) and African Caribbean (23.5%) participants (327 females, 413 males; mean (SD) age 71(7) years). Office blood pressure measurements were obtained on the same day when cerebral perfusion was assessed. The participants’ data were excluded from the analysis if records were incomplete and/or recorded grey matter perfusion values were lower than 20 ml/100 g/min. Data obtained in 690 participants were included in the final analysis. Recorded values of systolic blood pressure and patient history of hypertension were used to stratify the study cohort into 4 groups: i) individuals with normal blood pressure [243 participants; mean systolic blood pressure (SD) 117(9) mmHg; mean (SD) age 70(7) years]; ii) patients with untreated hypertension, not receiving any anti-hypertensive drugs [250 participants; systolic mean 145(12) mmHg; age 72(7) years]; iii) patients with hypertension, controlled on medication with a systolic blood pressure of <130 mmHg [94 participants; systolic mean 117(9) mmHg; age 71(6) years]; and iv) patients with hypertension, prescribed with anti-hypertensive drugs, but remaining uncontrolled on medication with

**Figure 1.** Cerebral perfusion in untreated, controlled, and uncontrolled hypertension. Summary plots illustrating the relationships between grey (a) and white (b) matter perfusion and systolic arterial blood pressure (SBP). Linear fit regression line is shown ± 95% CI. Participant’s medication status groups are indicated: (i) individuals with normal blood pressure, not taking any anti-hypertensive medication with a SBP of <130 mmHg; (ii) patients with untreated hypertension, not taking any anti-hypertensive medication with a SBP ≥130 mmHg; (iii) patients with controlled hypertension, taking anti-hypertensive medication with a SBP of <130 mmHg; and (iv) patients with hypertension, prescribed with anti-hypertensive drugs, but uncontrolled on medication with a SBP of ≥130 mmHg. (c) The relationship between age and cerebral perfusion measured by ASL. Linear fit regression line is shown ± 95% CI and (d,e) summary data illustrating the differences in grey and white matter perfusion between 4 groups of patients. Groups were compared using ANCOVA with age, BMI, and sex as covariants and Tukey’s multiple comparison correction for post-hoc analysis. Violin plots show arithmetic mean (central point) ± SD with the outline illustrating kernel probability density. Indicated P values were obtained in comparison to the normotensive group data.
a systolic blood pressure of $\geq 130\text{mmHg}$ [103 participants; systolic mean $144(12)\text{mmHg}$; age $72(6)$ years].

Accounting for the covariants of age, body mass index (BMI) and sex, a significant negative correlation between systolic arterial blood pressure and cerebral perfusion in both grey ($p = 0.01$, $R^2 = 0.05$) and white matter ($p = 0.001$, $R^2 = 0.06$) was observed across the whole patient cohort (Figure 1(a) to (c)). Subsequent group-wise analysis revealed a difference between participants with normal blood pressure and both unmedicated participants with hypertension ($p = 0.02$, grey matter; $p = 0.002$ white matter) and patients with high blood pressure, who were prescribed but remained uncontrolled on medication ($p = 0.004$, grey matter; $p = 0.007$; white matter). The mean CBF (SD) in the participants with normal blood pressure was $39(7)\text{mL/100 g/min}$ in the grey matter and $14.5(4)\text{mL/100 g/min}$ in the white matter ($n = 243$). The lowest values of CBF were recorded in the group of patients with high blood pressure that were uncontrolled on medication $36(6)\text{mL/100 g/min}$ in the grey matter and $13(3)\text{mL/100 g/min}$ in the white matter ($n = 103$; Figure 1(d) and (e)).

These data confirm that high systemic arterial blood pressure is associated with reduced cerebral perfusion. The data do not support the results of a previous study that reported no significant CBF differences between normotensive subjects and individuals with untreated hypertension. In a recent longitudinal study undertaken in older (mean age $77$ years) individuals with hypertension, the use of anti-hypertensive medication was found to be associated with lower grey matter CBF. In contrast, another recent study involving participants aged $50$ years or older (mean age $67.5$ years) showed that intensive anti-hypertensive treatment (to achieve systolic blood pressure target of $<120\text{mmHg}$) was associated with increased, rather than decreased, perfusion in the grey and white matter. Our analysis suggests that anti-hypertensive treatment has no deleterious effect on cerebral perfusion if systemic arterial blood pressure is controlled on medication and supports the conclusions of the meta-analysis conducted by Van Rijssel and colleagues. These findings highlight the importance of blood pressure control not only for the purpose of reducing the risk of stroke, cardiovascular disease, heart and renal failure, but also for the benefit of maintaining adequate cerebral blood flow and protecting the brain from harmful effects of chronically reduced perfusion.

**Declaration of conflicting interests**
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: AVG is a founder and Chief Scientific Officer for Afferent Medical Solutions. XG is a founder and shareholder of Gold Standard Phantoms, a company producing ASL perfusion phantoms. The other authors declare no competing interests.

**Funding**
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by The Wellcome Trust (AVG; ref: 200893 and 223057) and the British Heart Foundation (AVG; ref: RG/19/5/34463). AVG was supported by a Wellcome Senior Research Fellowship (ref: 200893). HM is supported by the Dutch Heart Foundation (03-004-2020-T049), by the Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and innovation programme (ASPIRE E1113701), provided by the Netherlands Enterprise Agency (RvO), and by the EU Joint Program for Neurodegenerative Disease Research, provided by the Netherlands Organisation for Health Research and Development and Alzheimer Nederland (DEBBIE JPND2020-568-106).

**ORCID iDs**

Isabel N Christie https://orcid.org/0000-0003-0982-0331

Henk JMM Mutsaerts https://orcid.org/0000-0003-0894-0307

Alun D Hughes https://orcid.org/0000-0001-5432-5271

**References**

1. Iadecola C and Gottesman RF. Neurovascular and cognitive dysfunction in hypertension. *Circ Res* 2019; 124: 1025–1044.

2. Ungvari Z, Toth P, Tarantini S, et al. Hypertension-induced cognitive impairment: from pathophysiology to public health. *Nat Rev Nephrol* 2021; 17: 639–654.

3. Webb AJS. Effects of vasodilating medications on cerebral haemodynamics in health and disease: systematic review and meta-analysis. *J. Hypertens* 2019; 37: 1119–1125.

4. van Rijssel AE, Stins BC, Beishon LC, et al. Effect of antihypertensive treatment on cerebral blood flow in older adults: a systematic review and Meta-analysis. *Hypertension* 2022; 79: 1067–1078.

5. Leeuwis AE, et al. Cerebral blood flow and cognitive functioning in a community-based, multi-ethnic cohort: the SABRE study. *Front Aging Neurosci* 2018; 10: 279.

6. Mutsaerts HJMM, Petr J, Groot P, et al. ExploreASL: an image processing pipeline for multi-center ASL perfusion MRI studies. *Neuroimage* 2020; 219: 117031.

7. Warnert EAH, Rodrigues JCL, Burchell AE, et al. Is high blood pressure self-protection for the brain? *Circ Res* 2016; 119: e140–e151.

8. van Dalen JW, Mutsaerts HJ, Petr J, et al. Longitudinal relation between blood pressure, antihypertensive use and cerebral blood flow, using arterial spin labelling MRI. *J Cereb Blood Flow Metab* 2021; 41: 1756–1766.

9. Dolui S, Detre JA, Gaussoin SA, et al. Association of intensive vs standard blood pressure control with cerebral blood flow: secondary analysis of the SPRINT MIND randomized clinical trial. *JAMA Neurol* 2022; 79: 380–389.